Evoke Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Evoke Pharma CEO'su Matt D'Onofrio, Mar2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 857.37K olup, şirket hissesi ve opsiyonları dahil olmak üzere 52.5% maaş ve 47.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler € 10.82K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 17.3 yıldır.

Anahtar bilgiler

Matt D'Onofrio

İcra Kurulu Başkanı

US$857.4k

Toplam tazminat

CEO maaş yüzdesi	52.5%
CEO görev süresi	less than a year
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	17.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Matt D'Onofrio'un ücretlendirmesi Evoke Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$857k	US$450k	-US$8m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$602k	US$417k	-US$8m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$1m	US$407k	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$828k	US$387k	-US$13m
Sep 30 2020	n/a	n/a	-US$12m
Jun 30 2020	n/a	n/a	-US$12m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$852k	US$372k	-US$7m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$831k	US$357k	-US$8m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$10m
Mar 31 2018	n/a	n/a	-US$9m
Dec 31 2017	US$780k	US$345k	-US$12m

Tazminat ve Piyasa: Matt 'nin toplam tazminatı ($USD 857.37K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 474.54K ).

Tazminat ve Kazançlar: Matt şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Matt D'Onofrio (54 yo)

less than a year

Görev süresi

US$857,371

Tazminat

Mr. Matthew J. D'Onofrio, also known as Matt, MBA, had been the Chief Business Officer and Executive Vice President at Evoke Pharma, Inc. since 2010 until 2023. He served as Treasurer and Secretary since M...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Matthew D'Onofrio	Co-Founder	less than a year	US$857.37k	0.20% € 10.8k
Marilyn Carlson	Chief Medical Officer	10.8yrs	US$728.49k	0.044% € 2.4k
Mark Kowieski	Chief Financial Officer	less than a year	Veri yok	0.051% € 2.7k
Christopher Quesenberry	Chief Commercial Officer - Gimoti (TM)	4.2yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: EV0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Matthew D'Onofrio	Co-Founder	less than a year	US$857.37k	0.20% € 10.8k
Kenneth Widder	Independent Director	17.3yrs	US$77.54k	0% € 0
Todd Brady	Independent Director	17.3yrs	US$79.43k	0.0034% € 183.4
Cam Garner	Independent Chairman of the Board	17.3yrs	US$102.95k	0.28% € 15.3k
Malcolm Hill	Independent Director	17.3yrs	US$79.18k	0.016% € 877.3
Vickie Reed	Independent Director	3.4yrs	US$85.31k	0% € 0
Benjamin Smeal	Director	no data	Veri yok	Veri yok

17.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EV0 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 17.3 yıldır).

Evoke Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Evoke Pharma, Inc. Announces Executive Changes

Insufficient new directors

Co-Founder recently sold €173k worth of stock

Recent updates

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023)

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.67 loss in 1Q 2023)

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.60 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$2.62 loss per share (vs US$3.18 loss in FY 2021)

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.73 loss in 3Q 2021)

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.85 loss in 2Q 2021)

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma, Inc. Announces the Launch of Wave 1 of an Innovative Social Media Campaign to Reach Patients Directly with Education About Diabetic Gastroparesis

Independent Director has left the company

No longer forecast to breakeven

Revenue misses expectations

Evoke Pharma, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: €2.00

Evoke Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

Evoke Pharma, Inc. Announces, Through its Marketing Partner, Eversana Life Science Services, LLC, Conducted an ATU (Awareness, Trial, and Usage) Study, Quantitative Survey to Measure Physician Awareness, Trial, and Product Usage, for GIMOTI

New 90-day low: €2.07

Co-Founder recently sold €173k worth of stock

New 90-day low: €2.37

New 90-day low: €2.70

New 90-day low: €3.26

Evoke Pharma, Inc. and Eversana Life Science Services, LLC Announce Commercial Launch of Gimoti™

New 90-day high - €3.60

CEO Tazminat Analizi

CEO

Görev süresi